Novel findings of 18β-glycyrrhetinic acid on sRAGE secretion through inhibition of transient receptor potential canonical channels in high-glucose environment

Biofactors. 2019 Jul;45(4):607-615. doi: 10.1002/biof.1517. Epub 2019 May 23.

Abstract

Enhancing soluble receptor for advanced glycation endproducts (sRAGE) is considered as a potent strategy for diabetes therapy. sRAGE secretion is regulated by calcium and transient receptor potential canonical (TRPC) channels. However, the role of TRPC channels in diabetes remains unknown. 18β-Glycyrrhetinic acid (18β-GA), produced from liquorice, has shown antidiabetic properties. This study was aimed to investigate the effect of 18β-GA on sRAGE secretion via TRPC channels in high glucose (HG)-induced THP-1 cells. HG treatment enhanced TRPC3 and TRPC6 expression and consequently caused reactive oxygen species (ROS) accumulation mediated through p47 nicotinamide-adenine dinucleotide phosphate oxidase and inducible nitric oxide synthase (iNOS) associated with uncoupling protein 2 (UCP2) decline and lower sRAGE secretion. Interestingly, 18β-GA showed the dramatic effects similar to Pyr3 or 2-aminoethyl diphenyl borinate inhibitors and effectively reversed HG-elicited mechanisms including that blocking TRPC3 and TRPC6 protein expressions, suppressing intracellular [Ca2+] concentration, decreasing expressions of ROS, p47s, and iNOS, but increasing UCP2 level and promoting sRAGE secretion. Therefore, 18β-GA provides a potential implication to diabetes mellitus and its complications.

Keywords: 18β-glycyrrhetinic acid; THP-1; TRPC; high glucose; sRAGE.

MeSH terms

  • Boron Compounds / pharmacology
  • Calcium / metabolism
  • Gene Expression Regulation
  • Glucose / antagonists & inhibitors*
  • Glucose / toxicity
  • Glycyrrhetinic Acid / analogs & derivatives*
  • Glycyrrhetinic Acid / isolation & purification
  • Glycyrrhetinic Acid / pharmacology
  • Glycyrrhiza / chemistry*
  • Humans
  • Hypoglycemic Agents / isolation & purification
  • Hypoglycemic Agents / pharmacology*
  • NADPH Oxidases / genetics
  • NADPH Oxidases / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism
  • Plant Extracts / chemistry
  • Pyrazoles / pharmacology
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism
  • Receptor for Advanced Glycation End Products / antagonists & inhibitors
  • Receptor for Advanced Glycation End Products / genetics*
  • Receptor for Advanced Glycation End Products / metabolism
  • Signal Transduction
  • THP-1 Cells
  • TRPC Cation Channels / antagonists & inhibitors
  • TRPC Cation Channels / genetics*
  • TRPC Cation Channels / metabolism
  • TRPC6 Cation Channel / antagonists & inhibitors
  • TRPC6 Cation Channel / genetics*
  • TRPC6 Cation Channel / metabolism
  • Uncoupling Protein 2 / genetics
  • Uncoupling Protein 2 / metabolism

Substances

  • 2-aminoethyl diphenylborinate
  • Boron Compounds
  • Hypoglycemic Agents
  • Plant Extracts
  • Pyrazoles
  • Reactive Oxygen Species
  • Receptor for Advanced Glycation End Products
  • TRPC Cation Channels
  • TRPC3 cation channel
  • TRPC6 Cation Channel
  • TRPC6 protein, human
  • Ucp2 protein, rat
  • Uncoupling Protein 2
  • ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate
  • sRAGE protein, human
  • 18alpha-glycyrrhetinic acid
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • NADPH Oxidases
  • neutrophil cytosolic factor 1
  • Glucose
  • Glycyrrhetinic Acid
  • Calcium